Lucid Capital initiated coverage of NervGen Pharma (NGEN) with a Buy rating and $18 price target The company’s lead clinical candidate, NVG-291, is about to enter a pivotal trial for spinal cord injury, specifically for chronic tetraplegia, the analyst tells investors in a research note. The firm sees a “significant unmet need” and a large unaddressed market.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGEN:
- NervGen Pharma price target raised to $12 from $10 at Maxim
- NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
- NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
- NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel
- NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury